Atuka

Atuka is a preclinical contract research organization (CRO) headquartered in Toronto, Canada, with additional state-of-the-art facilities in Suzhou, China. Founded in 2003 by Dr. Jonathan Brotchie, the company has dedicated itself to advancing the understanding and treatment of Parkinson's disease and other neurological disorders. Atuka's core mission is to accelerate the development of disease-modifying therapies for Parkinson's, a field where symptomatic treatments exist but no cure has yet been found. The company positions itself as offering "the world's best preclinical neuroscience," combining deep expertise in Parkinson's disease with an industry-leading range of rodent and non-human primate (NHP) models. Atuka provides tailored preclinical evaluation services for potential therapeutics across multiple modalities, including biologics (such as gene therapy) and small molecules. Unlike organizations that offer standardized approaches, Atuka designs each study according to the unique mode of action and potential indication of a partner's therapeutic, aiming for high translatability to Phase II clinical proof-of-concept. The company's expertise extends beyond Parkinson's to cognitive disorders, ALS, and other movement disorders such as dystonia and dyskinesia. Atuka is also a world expert in NHP research, with the capacity to conduct studies using up to 150 macaques. Since its founding, Atuka has been involved in the preclinical evaluation of more than 300 potential therapeutics, predominantly in Parkinson's disease, of which more than 30 have progressed to clinical trials. The company collaborates with partners across the pharmaceutical and biotechnology sectors, helping them make informed decisions at the critical interface between preclinical and clinical development. Atuka's scientific leadership includes Dr. Patrick Howson, Chief Innovation Officer, who is active in advancing the field through educational content and thought leadership. The company is a private entity and operates globally from its Canadian and Chinese facilities.

Atuka was founded in 2003 by Dr. Jonathan Brotchie in Toronto, Canada. From its inception, the company focused on preclinical neuroscience, specifically targeting Parkinson's disease, a neurodegenerative disorder for which only symptomatic treatments were available. The founding vision was to accelerate the discovery and development of disease-modifying therapies by providing high-quality, translatable preclinical models and expertise. In its early years, Atuka built a reputation for its deep understanding of Parkinson's disease biology and its ability to design customized preclinical studies. The company invested in developing a comprehensive suite of rodent and non-human primate (NHP) models, recognizing that NHP models, particularly macaques, offer superior translatability to human Parkinson's disease due to their similar neuroanatomy and motor circuitry. This investment positioned Atuka as a global leader in NHP research for Parkinson's. Over the years, Atuka expanded its capabilities to include gene therapy evaluation, biodistribution studies, and models for other neurological indications such as cognitive disorders, ALS, dystonia, and dyskinesia. The company also established a presence in China, opening state-of-the-art facilities in Suzhou to complement its Toronto headquarters. This dual-location strategy allowed Atuka to serve a global clientele and tap into the growing Asian biotech market. By the 2020s, Atuka had been involved in the preclinical evaluation of more than 300 potential therapeutics, predominantly for Parkinson's disease, with more than 30 advancing to clinical trials. This track record underscored the company's role as a critical partner for pharmaceutical and biotechnology companies seeking to bridge the gap between preclinical research and clinical development. Atuka's scientific leadership has been active in the broader research community. Dr. Patrick Howson, Chief Innovation Officer, has produced educational content on aligning in vivo models with biological classifications and has represented Atuka at major conferences such as the Michael J. Fox Foundation (MJFF) Therapeutics Conference. The company has also championed the adoption of EQIPD quality guidelines to enhance data integrity and reproducibility in biomedical research. As of the mid-2020s, Atuka remains a private company, continuing to operate from its facilities in Toronto and Suzhou, and maintaining its focus on preclinical neuroscience with the goal of accelerating cures for Parkinson's disease and other neurological disorders.

• 2026

  Chief Innovation Officer Dr. Patrick Howson released a video lecture on aligning in vivo models with biological classifications.

• 2025

  Participated in the 2025 MJFF Therapeutics Conference, sharing perspectives on Parkinson's research.

• 2003

  Atuka founded by Dr. Jonathan Brotchie in Toronto, Canada.

• Established state-of-the-art facilities in Suzhou, China, in addition to Toronto headquarters.

• Involved in preclinical evaluation of more than 300 potential therapeutics, with over 30 progressing to clinical trials.

Atuka positions itself as a premier preclinical CRO with unmatched expertise in Parkinson's disease and neuroscience, offering tailored, translatable models to accelerate the development of disease-modifying therapies.

• Preclinical evaluation services for Parkinson's disease

  Tailored preclinical programs to evaluate potential therapeutics for Parkinson's disease, including efficacy and target engagement studies.

• Rodent models of Parkinson's disease

  A comprehensive suite of rodent models for preclinical research in Parkinson's disease.

• Non-human primate (NHP) models of Parkinson's disease

  Industry-leading NHP models, with capacity for studies using up to 150 macaques, offering high translatability to human Parkinson's disease.

• Gene therapy preclinical evaluation

  Expertise in evaluating gene therapy approaches for Parkinson's and other neurological disorders.

• Biodistribution studies

  Studies to assess the distribution of therapeutics within the body, critical for gene therapy and biologics.

1. 1Atuka - A cure for Parkinson’s, faster, through the world’s best preclinical neuroscience.atuka.com
2. 2About Us - The world’s best preclinical neuroscience - Atukaatuka.com
3. 3Services - Atukaatuka.com
4. 4Atuka (Canada) - Wikidatawikidata.org